KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial.

Melanie Arnreiter, Moritz von Scheidt, Johannes M Albes, Tim Attmann, Andreas Boening, Yeong-Hoon Choi, Lenard Conradi, Bernhard C Danner, Andreas Fach, Ivar Friedrich, Herko Grubitzsch, Roland Heck, Alexander Joost, Christoph Knosalla, Martin Misfeld, Martin Oberhoffer, Julia Riebandt, Andreas Schaefer, Matthias Siepe, Thomas Walther, Gerhard Wimmer-Greinecker, Uwe Zeymer, Heribert Schunkert, Adnan Kastrati, Sigrid Sandner

Eur J Cardiothorac Surg 67(7) ezaf175

PMID40411761
PMCIDPMC12212761
DOI10.1093/ejcts/ezaf175
发表日期2025-05-24
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:森林图/亚组分析图;Figure 3:AI 判定为 other。
摘要

摘要

OBJECTIVES: Patients with extensive coronary artery disease (CAD) have a higher risk of cardiovascular events. This post hoc analysis of the Ticagrelor in CABG (TiCAB) trial examined the association of ticagrelor monotherapy versus aspirin with clinical outcomes after coronary artery bypass grafting (CABG) in relation to the extent of CAD. METHODS: The TiCAB trial randomized CABG patients to ticagrelor (90 mg twice daily) or aspirin (100 mg daily) for 12 months. Patients were stratified by SYNTAX score terciles: low (≤22), intermediate (23-32) and high (≥33). The primary end-point was major adverse cardiac and cerebrovascular events (MACCE) at 12 months, including cardiovascular death, myocardial infarction, stroke or repeat revascularization. Secondary end-points included individual MACCE components and major bleeding events. Cox proportional hazards models were used to assess treatment effects. RESULTS: Among 752 patients, 33.4% had low, 36.0% intermediate and 30.6% high SYNTAX scores (median 26.5 [20.0-33.0]). MACCE rates were similar across groups (low: 7.8%; intermediate: 9.2%; high: 8.8%; P = 0.87), though the incidence of repeat revascularization differed significantly among SYNTAX score groups (P = 0.02). Ticagrelor did not show a significant MACCE benefit over aspirin in any SYNTAX score group (low: HR 2.27, 95% CI 0.87-5.94; intermediate: HR 1.02, 95% CI 0.46-2.27; high: HR 1.76, 95% CI 0.70-4.46; Pint=0.41). Secondary outcomes, including bleeding, aligned with overall trial results. CONCLUSIONS: This analysis did not find a differential benefit of ticagrelor versus aspirin across CAD complexity levels as measured by the SYNTAX score. Further studies are warranted to refine antiplatelet strategies for patients with complex CAD undergoing CABG.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1: Cumulative event rate curves for the composite primary outcome of cardiovascular death, myocardial infarction, stroke or repeat revascularization by SYNTAX score terciles.
非 KM Figure
Figure 2Figure 2: Forest plot showing efficacy and safety outcomes at 12 months by SYNTAX score terciles (low [≤22], intermediate [23–32], high [≥33]) and randomized treatment. *Insufficient number of events in 1 or both treatment groups.
非 KM Figure
Figure 3Figure 3: Cumulative event rate curves for the composite primary outcome of cardiovascular death, myocardial infarction, stroke or repeat revascularization by SYNTAX score terciles and randomized treatment: ( A ) low (≤22) SYNTAX score; ( B ) intermediate (23–32) SYNTAX score; ( C ) high (≥33) SYNTAX score.
非 KM Figure